Treatment with 4-HPR encapsulated into nanoliposomes tagged with NGR peptides (NGR-NL[HPR]) that target the tumor endothelial cell marker aminopeptidase resulted in reduced tumor progression, inhibited tumor angiogenesis, and increased survival rates in a xenograft mouse model of neuroblastoma[22]. The gene discussed is CPQ; the disease is neoplasm.